Valuation: Nexstim Plc

Market Cap 79.13M 90.46M 72.97M 67.52M 128M 8.63B 130M 874M 343M 4.24B 340M 332M 14.69B P/E 2026 *
81.7x
P/E 2027 * 36.3x
Enterprise Value 77.03M 88.06M 71.04M 65.73M 125M 8.41B 127M 851M 333M 4.13B 331M 323M 14.3B EV / Sales 2026 *
6.07x
EV / Sales 2027 * 4.69x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-0.86% - - 90.46M
+2.86%+0.24%+24.97%+2.14% 195B
-0.86%-3.39%-22.07%+24.23% 146B
+0.40%-0.33%-56.30%-13.96% 66.87B
-2.47%-3.22%+18.32%+1.19% 52.59B
+0.38%-1.66%-27.47%-30.66% 43.85B
+3.50%+2.22%+10.13%+14.18% 37.73B
+2.44%-0.57%+8.00%+42.77% 37.03B
+1.27%-0.56%-18.57%-3.41% 30.07B
+0.03%-1.32%-14.32%-18.74% 29.43B
Average +0.72%-1.89%-8.59%+1.97% 70.92B
Weighted average by Cap. +1.12%-1.81%-4.16%+5.01%

Financials

2026 *2027 *
Net sales 12.7M 14.52M 11.71M 10.84M 20.57M 1.39B 20.91M 140M 54.98M 680M 54.5M 53.32M 2.36B 16.1M 18.4M 14.85M 13.74M 26.07M 1.76B 26.51M 178M 69.7M 863M 69.09M 67.6M 2.99B
Net income 1M 1.14M 922K 853K 1.62M 109M 1.65M 11.04M 4.33M 53.58M 4.29M 4.2M 186M 2.2M 2.51M 2.03M 1.88M 3.56M 240M 3.62M 24.3M 9.52M 118M 9.44M 9.24M 408M
Net Debt -2.1M -2.4M -1.94M -1.79M -3.4M -229M -3.46M -23.19M -9.09M -113M -9.01M -8.82M -390M -3.7M -4.23M -3.41M -3.16M -5.99M -404M -6.09M -40.86M -16.02M -198M -15.88M -15.53M -687M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-